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Oral bisphosphonates (BPs) are highly effective in preventing fractures and are 
recommended first-line therapies for patients with osteoporosis. We identified the 
incidence and predictors of treatment failure to oral BP therapy, defined as the 
incidence of ≥2 fractures while on treatment (≥2 FWOT) among users with high 
adherence. Fractures were considered after six months from treatment initiation and 
up to six months after discontinuation. Data from computerized records and pharmacy 
invoices were obtained from Sistema d‘Informació per al Desenvolupament de 
l‘Investigació en Atenció Primària (SIDIAP) (Catalonia, Spain) and Danish Health 
Registries (Denmark) for all incident users of oral BPs in 2006-2007 and 2000-2001 
respectively. Fine and Gray survival models using backward-stepwise selection (p‐
entry 0.049; p‐exit 0.10) and accounting for the competing risk of therapy cessation 
were used to identify predictors of ≥2 FWOT among patients having persisted with 
treatment ≥6months with overall medication possession ratio (MPR) ≥80%. Incidence 
of ≥2 FWOT was 2.4 (95% Confidence Interval (CI): 1.8-3.2) and 1.7 (95% CI: 1.2-
2.2) per 1000 Person Years (PYs) within Catalonia and Denmark respectively. Older 
age was predictive of ≥2FWOT in both Catalonian and Danish cohorts: subhazard 
ratio (SHR)=2.28 (95% CI: 1.11-4.68) and SHR=2.61 (95% CI: 0.98-6.95) 
respectively for 65 to <80 years and SHR=3.19 (95% CI: 1.33-7.69) and SHR=4.88 
(95% CI: 1.74-13.7) respectively for ≥80 years. Further significant predictors of ≥2 
FWOT identified within only one cohort were dementia, SHR=4.46 (95% CI: 1.02-
19.4) (SIDIAP) and history of recent or older fracture, SHR=3.40 (95% CI: 1.50-
7.68) and SHR=2.08 (95% CI: 1.04-4.15) respectively (Denmark). Even among 
highly adherent users of oral BP therapy, a minority sustain multiple fractures while 
on treatment. Older age was predictive of increased risk within both study 
populations, as was history of recent/old fracture and dementia within one but not 
 4 





A number of guidelines propose oral bisphosphonates (BPs) as first-line therapies for 
the prevention of fragility fractures in osteoporotic patients [1], and data from clinical 
trials suggest they can reduce the risk of fracture by up to 50% [2-4]. Such a large 
reduction in fracture risk is only achieved in patients persisting with treatment over 
several years [3], although 12 months has previously been considered sufficient time 
for BPs to reach efficacy [5] and significant benefits have been reported as early as 6 
months after treatment initiation [6]. However in actual practice relatively few 
patients starting oral BP therapy persist for an adequate length of time, with up to half 
of patients discontinuing treatment in the first 3-6 months [7] who hence remain at 
increased risk of fracture [8]. 
 
Furthermore, it has been shown in strictly controlled conditions such as randomized 
controlled trial (RCT) settings that even patients with high adherence to BPs may 
sustain fractures while on treatment [3, 4, 9, 10]. Indeed, no biological agent 
prescribed with the goal of fracture prevention can be expected to eliminate the risk of 
subsequent fracture completely. This makes it difficult to disentangle the individual 
roles of non-adherence and inadequate response in the incidence of new fractures 
among users of BPs. This is especially true for observational studies where data on 
anti-osteoporosis medications is usually scarce and often self-reported. 
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Subsequently, the issue of defining and characterising inadequate response to 
osteoporosis therapy has become increasingly topical in recent literature [5, 11-15]. 
Inadequate response has previously been defined as the occurrence of an incident 
fragility fracture despite having been on oral BP therapy for a minimum of 12 months 
[5]. Such a definition was similarly used by investigators of the Observational Study 
of Severe Osteoporosis (OSSO) in their evaluation of health-related quality of life 
among inadequate responders to anti-resorptive medications [16]. Other methods to 
assess response to osteoporosis treatment include a decrease in bone mineral density 
(BMD) greater than the least significant change (LSC) or insufficient improvement in 
biochemical markers of bone turnover, e.g. a decrease in βCTX and PINP in response 
to anti-resporptives that is less than the LSC [11]. 
 
A recent IOF consensus paper [11] has likewise provided pragmatic criteria for 
defining treatment failure in osteoporosis. Its authors recommend that ≥2 fragility 
fractures while on anti-resorptive drugs be considered indicative of treatment failure. 
The provided rationale was that data from clinical trials show risk of second or third 
fracture is reduced by 80-90% for treated vs. placebo and that fracture risk after an 
index fracture wanes over time.  
 
Despite the expectation that not all oral BP users will remain fracture free and that 
treatment failure can be inferred from the incidence of ≥2 fractures while on treatment 
(≥2 FWOT), data on the incidence and predictors of such occurrences in the general 
population are scarce. Treatment failure among bisphosphonate users has 
consequences both for the patient who remains at increased risk of fracture, and for 
healthcare providers as this phenomenon reduces cost-efficacy of treatment [17]. This 
is particularly relevant given the estimated 23% increase in osteoporosis prevalence 
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(as defined using the WHO diagnostic criteria) within Europe from 2010-2025 [18]. It 
would be of expected benefit therefore to be able to identify which patients are most 
at risk of multiple fractures while adhering to treatment so that suitable alterations to 
either a proposed or an existing treatment regimen may be considered.  
 
The primary objective of the present analysis was to identify the key predictors of ≥2 
FWOT during oral BP therapy in order to further elucidate the mechanisms of 
treatment failure among users remaining on therapy with high adherence (at least 6 
months persistence with overall medication possession ratio (MPR) ≥80%).  
 
MATERIALS AND METHODS 
 
Study population and source of data 
Sources of data used were The Danish Health Registries and Sistema d‘Informació 
per al Desenvolupament de l‘Investigació en Atenció Primària (SIDIAP) database. 
These have both been described in detail elsewhere [19, 20], and will therefore only 
be described briefly here. Danish data incorporates The National Prescriptions 
Database containing all filled prescriptions in the country since 1995, The National 
Hospital Discharge Register and National Cause of Death Register. SIDIAP covers a 
population of about 5 million patients (80% of the total population of Catalonia, 
Spain) and comprises the clinical and referral events registered by primary care health 
professionals (GPs and nurses) and administrative staff, demographic information, 
prescription and corresponding pharmacy invoicing data, specialist referrals, primary 
care laboratory test results, hospital admissions, and their major outcomes [21].  
Both the Danish Health Registries and SIDIAP were searched to identify all incident 
users of oral BPs (excluding high-dose oral BPs) for the period January 1st 2000 to 
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December 31st 2001 and January 1st 2006 to December 31st 2007 respectively with no 
BP prescription in the previous 12 months. Eligible participants aged below 40 years, 
those with a diagnosis of Paget disease and previous users of any antiosteoporosis 
drug (except calcium or vitamin D supplements) in the year prior to the first 
prescription of oral BPs were excluded. Users of intravenous bisphosphonates were 
not included due to limitations in accurately tracking this form of treatment using 
prescription data. Only users with a minimum of 6 months treatment persistence and 
high refill compliance (MPR ≥80%) were included in the main analysis. MPR is 
calculated as the proportion of days covered with therapy between the first and the 
last prescription of BPs (total number of defined daily doses [DDDs] purchased 
divided by the number of days between the first day of the first prescription and last 
day of the last prescription). 
 
Outcome: Ascertainment of ≥2FWOT 
Osteoporotic fractures (of any site except fingers, toes and skull/face) were identified 
in Danish and SIDIAP data using ICD codes for the period 2000-2008 and 2006-2011 
respectively (the list of codes used is provided in Supplementary Table 1). Fractures 
were included if they occurred after 6 months from starting therapy, so as to account 
for the delayed effects of BPs on bone, and before the end of study follow-up if 
remaining on treatment, or before a 6 month ‘wash-out’ after treatment 
discontinuation (given the known carry-over effect of BPs on bone metabolism). 
Treatment discontinuation was defined as last date for which medication was 
available on the last prescription before a 6-month refill gap in medication. Only 
fractures sustained on a date with no other incident fracture were considered, the 
rationale being to avoid inclusion of fractures arising from the same/high trauma 
event. Second fractures sustained at the same site as the first were only counted if 
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occurring after the elapse of six months in order to reduce the inclusion of 
readmissions/duplicate coding.  
 
Potential predictors of ≥2 FWOT 
Potential risk factors of ≥2 FWOT were assessed at the time of first oral BP 
prescription and defined a priori based on previous literature. These included the 
following: age (<65 years, 65 to <80 years, ≥80 years), gender, history of previous 
osteoporotic fracture (none, old fracture (≥6 months before starting oral therapy), 
recent fracture (<6months before starting therapy)), concomitant medications (proton 
pump inhibitors (PPI), oral corticosteroids (equivalent to prednisolone 5 mg daily for 
three month or more) and hormone replacement therapy (HRT)) and clinical diagnosis 
of pre-existing comorbid conditions (inflammatory arthritis, a neurological condition 
(stroke, Parkinson’s disease or multiple sclerosis), and dementia). Body mass index 
(BMI) (<25, 25-35 and ≥35 kg/m2) and smoking status (current, Ex- and non-smoker) 




Independent risk factors of time to second fracture while on oral BP treatment were 
identified for users within Danish Health Registries and SIDIAP database using 
multivariable Fine and Gray survival regression models to take into account the 
competing risk of treatment discontinuation [22]. The two study populations were 
analysed separately and all potential predictors (as described above) were assessed in 
univariate models and using backward-stepwise selection, whereby a parsimonious 
multivariable model was identified from the full model using cut-offs of p‐entry 0.049 
and p‐exit 0.10. Index date for these models was six months after treatment initiation 
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and only fractures sustained during continued persistence to treatment, or up to six 
months after discontinuation were considered. Patients were censored at date of death 
or end of follow-up. Therapy discontinuation was entered into these models as a 
competing risk given that cessation, by definition, precluded future ‘while on 
treatment’ events. Models were also run stratified by gender. STATA v13 was used 
for all statistical analyses, under permit 702538 from Statistics Denmark for analysis 
of Danish Health Registries data. 
Sensitivity analyses 
Two sensitivity analyses of predictors of ≥2 FWOT were carried out, one in which 
fractures were included if occurring on the same date as other fractures and another 
where a 12 month instead of 6 month period was used to allow for time to drug 
efficacy. 
 
Additionally, an analysis of all eligible oral BP users was used (Figure 1) to 
investigate treatment failure as defined by ≥2 fractures from at least 6 months after 
treatment initiation and during continued follow up, irrespective of persistence or re-
fill compliance (in an intention-to-treat (ITT)-like approach). This alternative 
approach addressed the broader public health context of treatment failure, 
incorporating both aspects of failure of drug and failure of adherence in the process of 
treatment not achieving the goal for which it was prescribed, i.e. fracture prevention. 
Standard multivariable Cox regression methods were used to identify independent 





The total number of treatment-naïve patients who started oral BP therapy was 14,815 
within DHR and 22,355 within SIDIAP during the two years of recruitment into each 
study cohort. 13,949 (Denmark) and 21,385 (SIDIAP) patients were remaining who 
met the inclusion criteria (Figure 1). Of these, 7,885 (56.5%) and 7,449 (34.8%) 
respectively persisted for a minimum of 6 months with an overall high MPR of ≥80% 
and were thus included in the main analysis (Figure 1). Baseline characteristics 
among these users and for all eligible treatment naïve oral BP users, irrespective of 
adherence are included in Table 1. 
 
Mean follow-up “on treatment” was 3.5 years within Denmark and 2.8 years within 
Catalonia, for a total of 27,870 and 20,598 patient-years (PYs) respectively. 
Occurrence of ≥2 FWOT was 46 (0.6%) for Denmark and 50 (0.7%) for SIDIAP, 
corresponding to an unadjusted incidence rate within Danish Health Registries of 
1.7/1,000 person years (95% confidence interval [CI]: 1.2-2.2) and within SIDIAP of 
2.4/1,000 person years (95% CI: 1.8-3.2). Cumulative incidence function plots are 
displayed in Figure 2. The majority of the fractures captured were 
clinical/symptomatic fractures; of the incident second fractures while on treatment, 43 
(93%) and 41 (88%) were non-vertebral within Danish Health Registries and SIDIAP 
respectively, reflecting the general under-reporting of vertebral fractures outside 
clinical trial settings. Rates remained unchanged in sensitivity analyses using a 12-
month lag for time to treatment effect (data not shown), but were higher when same 
date fracture were included: 2.7/1000 PYs (95% CI: 2.1-3.3) (Denmark) and 3.3/1000 
PYs (95% CI: 2.6-4.1) (SIDIAP). 
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For SIDIAP the incidence rate of second fracture among all incident oral BP users, 
irrespective of adherence was 2.5/1,000 PYs (95% CI: 2.2-2.9). Within Denmark this 
rate was 14.2/1,000 PYs (95% CI: 13.4-15.1) (Table 2). 
 
Older age (65 to <80 years and ≥80 years) was identified as an independent predictor 
of ≥2 FWOT within both Danish and SIDIAP ‘on treatment’ cohorts (Table 3). 
Further independent predictors of ≥2 FWOT were previous diagnosis of dementia in 
SIDIAP (but not Denmark) and history of recent or older fracture in Denmark (but not 
in SIDIAP) (Table 3). Cumulative incidence function plots stratified by these 
predictors are provided (Figures 3-5). 
 
When fractures occurring on the same days with other fractures were included as a 
sensitivity analysis, history of recent fracture became predictive of ≥2 FWOT within 
SIDIAP (sub-hazard ratio (SHR)=2.10 (95% CI: 1.05-4.20)) (Supplementary Table 
2). Likewise within Denmark, dementia became a significant risk factor of ≥2 FWOT 
(SHR=4.30 (95% CI: 1.47-12.60)) although it no longer did within SIDIAP 
(Supplementary Table 2). Independent predictors from the main analysis remained 
unchanged when a 12-month period was used for delayed treatment effect; with the 
exception that dementia was no longer a significant risk factor within the SIDIAP 
cohort (Supplementary Table 3). 
 
In the analysis of all incident users, irrespective of adherence, several significant 
predictors were identified in addition to those identified from the ‘on treatment’ 
approach (Supplementary Table 4). PPI use was predictive of second fracture within 
both study populations: HR=1.37 (95% CI: 1.17-1.61) for Denmark, and HR=1.58 
(95% CI: 1.13-2.20) for SIDIAP. Rheumatoid arthritis was also predictive in 
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Denmark: HR=1.61 (95% CI: 1.28-2.04). Conversely, male gender was found to be 
protective for both Denmark and SIDIAP: HR=0.64 (95% CI: 0.51-0.81) and 
HR=0.45 (95% CI: 0.29-0.71) respectively, as was HRT use within Denmark only 
(HR=0.83 (95% CI: 0.69-0.99)). Key findings were unaltered when analyses were run 
separately by gender, although predictors could not be identified among males only 




This binational retrospective cohort study reports a minority of oral BP users will 
proceed to suffer at least two fragility fractures, at a rate of between 1.7 (95% CI: 1.2-
2.2)/1000 PYs (Denmark) and 2.4 (95% CI: 1.8-3.2)/1000 PYs (Catalonia, Spain), 
despite remaining adherent to medication. In addition, we report here several key risk 
factors of ≥2 FWOT as identified among ‘on treatment’ users either within one or 
both study populations.  
Previous observational studies [14, 23] have reported between 1.3% and 15.5% of 
persistent BP users fracture at least twice while on treatment over a 3-year period. In 
terms of RCT settings, the rate of two or more clinical fractures among women while 
on alendronate treatment within the Fracture Intervention Trial (FIT) was 
approximately 0.8/100 PYs at risk [24]. Incidence of at least two (radiographic) 
vertebral fractures after 1 year among Risedronate-treated women within the 
Vertebral Efficiency with Risedronate Therapy (VERT) trial was 0.3% [25]. To our 
knowledge this is the first observational study to report on the incidence rate of ≥2 
FWOT for oral BP users within the general population. In main analyses we used a 
conservative definition of fracture - including only fractures sustained on days with 
no other fracture, after a lag period of six months from first to second fracture if at the 
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same site and only among users with at least 6 months persistence to treatment with 
overall high MPR (≥80%). 
Incidence rates of ≥2 FWOT were similar between the “on treatment” cohorts from 
the two countries, although non-significantly higher in Catalonia, Spain. It is worth 
noting several differences in the baseline characteristics between the “on treatment” 
cohorts from the two study populations (Table 1). The proportion of females and PPI 
users was significantly higher in SIDIAP, with less than a fifth of the number of HRT 
users compared to Denmark. The reason for the higher extent of HRT use in Denmark 
compared with Catalonia may be a function of time rather than geography as 
recruitment into the Danish study cohort began six years earlier than in Catalonia and 
this preceded the decline in worldwide use of HRT that followed on from publication 
of the Women’s Health Initiative RCT results on adverse events with HRT [26]. 
Secular trends may also have caused the differences in PPI exposure. 
 
Among all incident oral BP users within Denmark, the incidence rate of second 
fracture was approximately 8-fold higher compared to the Danish cohort of adherent 
patients considered “on treatment”. Conversely, it was surprising to find no 
significant change in rates between all incident oral BP users and those “on treatment” 
using the SIDIAP database, although fracture incidence during antiresorptive therapy 
has elsewhere been reported to be independent of compliance [15].  
 
The rates of second fracture among users “on treatment” are not directly comparable 
with those among all-incident users as these are different groups of users whose 
baseline risk is unlikely to be the same. However, data from RCTs can be inferred 
here. The Fracture Intervention Trial indicated a 90% reduction for multiple vertebral 
fracture associated with Alendronate use [27], as was also found for Risedronate use Formatted: Font color: Auto
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in the VERT trial [25]. In this context, the 88% lower incidence of second fracture 
among adherent vs. all-incident users is not an implausible finding. As previously 
noted though, comparison of rates should be made with caution given potential non-
equivalence of baseline risk. While we identified any differences in baseline gender, 
age, previous fracture history, PPI, steroids, HRT, dementia and rheumatoid arthritis - 
and found the all-incident cohort to be slightly frailer - we were not able to examine 
other potentially confounding factors such as smoking status, parental history of hip 
fracture, BMI, alcohol or use of Calcium/Vitamin D supplements. These factors may 
have been unbalanced in the two groups and may have contributed to some of the 
observed difference in fracture rates in addition to the effects of bisphosphonate 
adherence. Conversely, within SIDIAP the proportion of men in the “on treatment” 
cohort is less than half that among all-incident users (Table 1). This suggests a 
concentration of high-risk patients within the SIDIAP “on treatment” cohort, possibly 
due to better adherence among those with greater (correct) perception of fracture risk. 
There is also large potential within SIDIAP for further unobserved non-equivalence in 
baseline characteristics between all-incident users and those “on treatment” given that 
approximately two thirds of oral BP users failed the persistence and/or compliance 
criteria for the main analysis. 
 
Moreover, the Danish all-incident oral BP population contains a more fragile patient 
mix compared to that in Catalonia (Table 1), which likely contributes to the 
significantly higher incidence rate of second fracture after treatment initiation within 
Denmark relative to SIDIAP, irrespective of treatment adherence. Worth noting from 
the literature is a recent report estimating that Denmark has the highest ten-year 
probability of major osteoporotic fracture out of 20 European countries; over twice 
that of Spain that has the lowest (estimated using the FRAX algorithm) [18]. Also of 
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note within the same report was a 3-fold range in hip fracture incidence, in which 
Denmark (2004) was highest and Spain (1984-91) third lowest [18].  
 
Incidence (per 1000 PYs) of first fracture has previously been reported among the 
general population for these study populations [28, 29], and were as follows: hip=4.9, 
wrist=4.8, forearm=5.9, vertebral=1.3, humerus=4.1 and pelvis=0.7 (Danish Health 
Registries); hip=2.23, wrist/forearm=2.56, clinical spine=1.98, humerus=1.55 and 
pelvis=0.04 (SIDIAP). 
 
Using competing risk survival methods to study predictors of ≥2 FWOT we have 
identified oral BP users of older age to be at greater risk in both of two large study 
populations. Furthermore, those with a history of recent/older fracture or with 
dementia were at increased risk within one but not both of the populations under 
study. All independent predictors identified among users within only one study 
population (Denmark or SIDIAP) were found to be predictive in the other when 
fractures occurring on the same date were included as a sensitivity analysis. Failure to 
identify all such characteristics as risk factors in the main analysis may be due to the 
comparatively low number of users experiencing a second fracture while on 
treatment. Independent predictors of ≥2 FWOT reported by other studies [14, 23] 
have included previous history of fracture, low levels of vitamin D, current smoking 
status and baseline alkaline phosphatase total activity levels. History of fracture has 
also been identified as a predictor of single fracture while on BP treatment [5, 13, 19, 
20], as has older age [15, 20] and dementia [19]. 
Previous studies have frequently shown that low compliance leads to higher fracture 
risk [8]. In parallel, some reports have shown that previous use of HRT is related to 
better compliance with oral BPs [30]. The appearance of HRT (Denmark) as a 
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protective factor for second fracture in the analysis of all incident users but not in the 
competing risk analysis of ≥2 FWOT might therefore be due to an indirect effect on 
fracture reduction via altered therapy adherence. Similarly, the gender effect (lower 
risk of second fracture among men treated with oral BPs) identified in both Denmark 
and SIDIAP could be associated with poorer adherence which would explain why this 
was not relevant in the main analysis of predictors of ≥ 2FWOT. The finding of PPI 
use (Denmark and SIDIAP) and rheumatoid arthritis (Denmark only) as significantly 
predictive of second fracture among all-incident users is clinically plausible and these 
factors have previously been reported as risk factors of single FWOT within the 
SIDIAP population [20]. Moreover, it has recently been shown that the anti-fracture 
efficacy of oral alendronate is significantly reduced when taken concomitantly with 
PPIs [31]; a finding further confirmed in a more recent report using the Danish data 
[19]. Lack of association between these variables and greater risk of ≥2 FWOT as 
reported here may be due to lack of power within our comparatively smaller sample 
size of those “on treatment” compared to all incident users. 
A variety of factors likely contribute to the process of treatment failure among oral 
BP users. While we have addressed the issue of discontinuation to therapy and low 
refill compliance in our main analysis, the failure of treatment as reported here might 
be the result of poor absorption due to users not taking medications as per instructions 
of prescription. Another reason may be divergent responses of bone to BPs due to 
variation in severity of bone structural damage [11, 23]. In the presence of continuous 
bone remodeling with negative balance, weakening in the microarchitecture of bone 
may have become too advanced for antiresorptives to be effectual in restoring bone 
mechanical competence. In other words, the oral BPs are prescribed “too late” in the 
natural history of bone deterioration in order to adequately reduce fracture risk. Also, 
though anti-resorptives reduce the number of stress risers on the surface of bone 
 17 
trabeculae and cortices, which is a prominent issue in high turnover states, they are 
likely ineffective when it comes to reversing accumulation of microdamage and 
advanced glycation end products as seen in low turnover states and bone ageing [32, 
33]. Other risk factors such as recurrent falls or adverse hip geometry are also 
unlikely to be modified by bisphosphonates.  
The IOF CSA Inadequate Response Working Group state that if treatment adherence 
cannot be further improved then treatment should be changed under the circumstances 
of two or more incident fragility fractures [11]. There is a need for further studies to 
demonstrate whether a patient failing on one treatment will respond favorably to an 
alternative, and our findings here can inform investigations into more personalized 
strategies for reducing fracture risk for high risk individuals. In the present absence of 
such evidence for effectiveness of alternatives, three general rules were recommended 
by the working group: 1) a weaker anti-resorptive is reasonably replaced by a more 
potent drug of the same class, 2) an oral drug is reasonably replaced by an injected 
drug and 3) a strong anti-resorptive is reasonably replaced by an anabolic agent.  
Strengths of our study are the representativeness of the data used: Danish Health 
Registries covers the whole of Denmark while SIDIAP covers a highly representative 
sample of more than 80% of the total population of Catalonia [21]. The definition of 
second fracture used was conservative, addressing the issues of trauma events (same-
date fracture not included) and re-coding (second fracture only included if at different 
site or after a 6 month lag). In addition, the information gathered on dispensed BPs is 
detailed, and likely to be more reliable than patient reports or GP prescriptions. 
The main limitation in our analysis is the lack of individual x-ray validation of the 
fractures observed in SIDIAP and Denmark, although coding of clinical fractures in 
both data sources has been validated and shown to be highly specific [28, 34]. 
Formatted: Font color: Auto
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Another is the use of MPR as a measure of adherence which assumes the drug is 
taken once dispensed, although MPR has been widely used elsewhere [12, 14, 19, 20, 
35]. As noted in a previous analysis using the Danish data, there is the possibility such 
a finding as dementia being predictive of fracture while on treatment may be an 
artifact of an artificially inflated MPR among dementia patients due to medications 
being delivered to them yet who in actual practice may fail to take them as prescribed. 
Also, the nature of our study unfortunately did not permit the analysis of bone 
turnover markers or bone mineral density decline that may otherwise have provided 
insight into the biological mechanisms of inadequate response to BPs. Finally, the risk 
reductions found in the original RCT of alendronate [27] was calculated after 
exclusion of high impact fractures while our analysis included fractures irrespective 
of trauma mechanism (except multiple fractures occurring on the same date, 
suggesting high impact trauma). Inclusion of some high impact fractures in the 




We conclude that oral BP therapy fails for a small proportion of users, as defined by 
the incidence of ≥2 FWOT. Older age was associated with higher risk in both 
Catalonia and Denmark. History of recent/old fracture and previous diagnosis of 
dementia were predictive of ≥2 FWOT within one but not both study populations. A 
number of clinical variables were additionally predictive of two or more fractures, 
irrespective of adherence. Information on all these variables is readily available in 
actual practice conditions and could be used to facilitate the identification of patients 
at higher risk of experiencing treatment failure. Additional and/or alternative 
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Figure 1: Population flow diagram  
 
Figure 2: Cumulative incidence function plots of second fracture while on oral BP 
treatment within SIDIAP and Denmark. Estimated using competing risk model 
adjusting for age and previous fracture history 
 
Figure 3: Cumulative incidence function plots of second fracture while on oral BP 
treatment within SIDIAP and Denmark, by age category. Estimated using competing 
risk model adjusting for previous fracture history 
 
Figure 4: Cumulative incidence function plots of second fracture while on oral BP 
treatment within SIDIAP and Denmark, by previous fracture history. Estimated using 
competing risk model adjusting for age. 
 
Figure 5: Cumulative incidence function plots of second fracture while on oral BP 
treatment within SIDIAP and Denmark, by baseline dementia status. Estimated using 

















n %* n %* n %* n %*
Sex,	male 5119 24% 750 10% 2202 16% 1,251 16%
Age,	years
<65	years 8782 41% 2866 39% 3814 27% 2,268 29%
65	to	<80	years 9543 45% 3619 49% 7149 51% 4,113 52%
≥80	years 3060 14% 964 13% 2986 21% 1,504 19%
Previous	fracture
No 18,308 86% 6088 82% 10,266 74% 6,042 77%
>6m	ago 2,018 9% 885 12% 2,551 18% 1,336 17%
<6m	ago 1,059 5% 476 6% 1,132 8% 507 6%
PPI	user 12,804 60% 4546 61% 2,145 15% 1,106 14%
Oral	corticosteriod	user 3,266 15% 1245 17% 3,630 26% 2,059 26%
HRT	user 567 3% 2034 15% 1,144 15%
Dementia 276 1% 53 1% 126 1% 66 1%
Neurological	conditions 860 4% 245 3% 666 5% 379 5%
Rheumatoid	arthritis 496 2% 221 3% 795 6% 465 6%
BMI
<25 3121 15% 1221 16% - - - -
25-35 9295 44% 3336 45% - - - -
>35 1307 6% 468 6% - - - -
Missing 7662 36% 2424 33% - - - -
Smoking
Never 15219 71% 5852 79% - - - -
Ex-Smoker 2126 10% 488 7% - - - -
Current 1636 8% 395 5% - - - -
Missing 2404 11% 714 10% - - - -
*	percentages	may	not	equal	100%	due	to	rounding
all	incident	users1	
(N=21,385)
adherent	users2	
(N=7,449)
all	incident	users1	
(N=13,949)
adherent	users2	
(N=7,885)
SIDIAP	(N=7,449) Danish	Health	Registries	(N=7,885)
Table	1:	Baseline	characteristics	among	incident	oral	bisphosphonate	users	within	the	SIDIAP	database	
and	Danish	Health	Registries
1	with	a	minimum	of	6	months	persistence	and	overall	MPR≥80%,
2	all	incident	users,	irrespective	of	persistence	or	overall	MPR
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p
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